Recent advances in obesity pharmacotherapy, particularly with glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs), have the potential to transform obesity and type 2 diabetes mellitus (T2DM) care by promoting marked weight loss, improving glycaemic control and addressing multiple obesity‐related comorbidities, with added cardio‐renal benefits. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.